金振口服液联合吸入用乙酰半胱氨酸治疗痰热壅肺证小儿支气管炎的临床研究

Clinical Study of Jinzhen Oral Liquid Combined with Inhalation of Acetylcysteine in the Treatment of Bronchitis in Children with Phlegm-heat Obstructing the Lung

目的探讨金振口服液联合吸入用乙酰半胱氨酸在痰热壅肺证小儿支气管炎中的效果。方法选取2021年1~12月某院收治的98例痰热壅肺证小儿支气管炎患儿,按随机数字表法分为两组,各49例。对照组给予常规对症治疗+吸入用乙酰半胱氨酸治疗,观察组于此基础上加用金振口服液治疗,连续治疗1周,并于治疗后随访1个月。对比两组临床疗效、症状消退时间、炎性因子水平、生活质量、不良反应。结果观察组治疗总有效率[93.88%(46/49)]高于对照组[79.59%(39/49)],退热时间[(2.19±0.45)d]、咳嗽消失时间[(3.46±0.48)d]、喘息消失时间[(3.71±0.42)d]、肺啰音消失时间[(4.15±0.32)d]均短于对照组[(3.55±0.63),(5.23±0.62),(5.36±0.58),(5.89±0.43)d],差异有统计学意义(P<0.05)。治疗前,两组白细胞计数(WBC)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)相比,差异无统计学意义(P>0.05);治疗7 d后,观察组WBC[(11.06±0.89)×10^(9)·L^(-1)]、CRP[(9.52±1.03)mg·L^(-1)]、TNF-α[(73.67±4.58)pg·mL^(-1)]低于对照组[(14.23±1.59)×10^(9)·L^(-1)、(12.44±1.59)mg·L^(-1)、(105.23±6.35)pg·mL^(-1)],差异有统计学意义(P<0.05)。治疗前,两组儿童生存质量测定量表(PedsQL4.0)内各维度评分相比,差异无统计学意义(P>0.05);治疗后1个月,观察组PedsQL4.0内各维度评分[(27.48±3.15),(16.26±1.97),(16.38±1.67),(16.23±1.56)分]均高于对照组[(22.39±2.48),(14.69±1.45),(14.39±1.35),(13.89±1.23)分],差异有统计学意义(P<0.05);两组治疗时均无不良反应。结论金振口服液联合吸入用乙酰半胱氨酸治疗痰热壅肺证小儿支气管炎患儿效果确切,可有效减轻患儿的症状,降低机体炎性因子水平,改善其生活质量,且不会增加不良反应,值得临床的大力推广。

OBJECTIVE To investigate the effect of Jinzhen oral liquid combined with inhalation of acetylcysteine in the treatment of bronchitis in children with phlegm-heat obstructing the lung.METHODS A total of 98 children with bronchitis and phlegm-heat obstructing the lung syndrome who were admitted to a hospital from January to December 2021 were selected and divided into two groups according to the random number table method,with 49 cases in each group.The control group was given conventional symptomatic treatment with inhaled acetylcysteine treatment,and the observation group was additionally given Jinzhen oral liquid treatment on this basis,for 1 week continuously,and followed up for 1 month after treatment.The clinical efficacy,symptom subsidence time,inflammatory factor levels,quality of life,and adverse reactions were compared between the two groups.RESULTS The total effective rate[93.88%(46/49)]of the observation group was higher than that of the control group[79.59%(39/49)],the time for fever reduction[(2.19±0.45)d],and the time for cough disappearance[(3.46±0.48)d],wheezing disappearance time[(3.71±0.42)d],and lung rale disappearance time[(4.15±0.32)d]were all shorter than those in the control group[(3.55±0.63),(5.23±0.62),(5.36±0.58),(5.89±0.43)d],the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in white blood cell count(WBC),C-reactive protein(CRP)and tumor necrosis factor-α(TNF-α)between the two groups(P>0.05).[(11.06±0.89)×10^(9)·L^(-1)],CRP[(9.52±1.03)mg·L^(-1)],TNF-α[(73.67±4.58)pg·mL^(-1)]were lower than the control group[(14.23±1.59)×10^(9)·L^(-1),(12.44±1.59)mg·L^(-1),(105.23±6.35)pg·mL^(-1)],the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in the scores of each dimension in the children's quality of life measuring scale(PedsQL4.0)between the two groups(P>0.05).1 month after treatment,the scores of each dimension in the observation group PedsQL4.0[(27.48±3.15),(16.26±1.97),(16.38±1.67),(16.23±1.56)points]were higher than the control group[(22.39±2.48),(14.69±1.45),(14.39±1.35),(13.89±1.23)points],the difference was statistically significant(P<0.05).There were no adverse reactions in the two groups during treatment.CONCLUSION Jinzhen oral liquid combined with inhalation of acetylcysteine can effectively reduce the symptoms in the treatment of children with phlegm-heat obstructing lung syndrome children with bronchitis and can reduce the level of inflammatory factors,improve the quality of life,and less increase adverse reactions happened.it is worthy of vigorous clinical promotion.